Mark Harris, PhD, MBA
Founder & Chief Innovation Officer
Mark founded Concert Genetics (formerly NextGxDx) in 2010 to bring efficiency to the genetic testing market. He has over 15 years of experience in molecular biology, technology commercialization, and executive leadership. Today, as Chief Innovation Officer, Mark leads a dynamic team of software engineers, data scientists and clinicians to advance the company’s product suite and outline its roadmap for the future.
Deeply involved in the entrepreneurial ecosystem, Mark has been a mentor for several accelerator programs and an advisor for startup companies and investment groups. He frequently speaks at healthcare, genetics, and technology industry events.
In 2010, before founding Concert Genetics, Mark worked for Athena Diagnostics, leading a team that designed one of the first implementations of a Next Generation Sequencing platform for a commercial lab. He earned his PhD in Cancer Biology and a Master of Business Administration from Vanderbilt University.
About Concert Genetics
Genetic testing is the lynchpin of precision medicine, but the rapid pace of change in the market makes it enormously complex. Today, there are more than 65,000 unique genetic testing products on the market, and an average of 10 new products are added each day. This growth confounds the processes through which tests are ordered, resulted, billed and reimbursed.
Founded in 2010 with a vision to simplify this complexity, Concert Genetics (formerly NextGxDx, Inc.) launched as a healthcare technology company dedicated to streamlining the genetic test selection, ordering, payment and management for clinicians, hospitals, laboratories and health plans.